Also The sale of only 26,660 shares in itself is not big news. It would be interesting to see the timing and nature of these transactions that were worthy of being aired on CNBC.
It will be interesting to see just how large of a position was traded, since Nasdaq shows the last reported position by AlphaOne was sold as of June 30, 2013. He said he sold his entire position, but Maria Bartiromo intimated that he had held from below $20, which based on the Nasdaq reporting could not be the case. Again this can be seen on Nasdaq site for institutional holdings on FB page 48:
ALPHAONE INVESTMENT SERVICES, LLC 06/30/2013 0 (26,660) Sold Out
What was said and what was reported according to Nasdaq seems to be two different things. Btw it was Maria that said he was in below 20 and he did not deny it.
Can we assume that if Daniel Niles' (AlphaOne) purchase was not part of the 9/30/13 (last) reporting on Nasdaq and the low after that date was $45.26 on Oct 9th at the Oct low, then he could only have a maximum profit of around $6.00 a share, and much less if they were purchased into the earnings runup?
Interesting that Nasdaq shows Alphaone sold its 26,660 shares on or prior to 6/30/13. That means they must have repurchased shares and sold them as opposed to holding them from below $20 per Maria's comment. Get the story straight CNBC! Btw at the end of June FB was still below $25. lol
See page 48 on the Nasdaq site under Instituitional ownership
Nice set of potential applications to be applied based on licensing agreement:
This agreement enables VaxLogic to immediately utilize the QS-21 Stimulon adjuvant in development for a nicotine addiction vaccine, and contemplates expansion into the following additional vaccine indications: poison ivy, peanut allergy, insect allergy, shellfish allergy, allergic rhinitis, and allergic asthma. VaxLogic will develop these vaccine candidates using Agenus' QS-21 Stimulon adjuvant and select defined antigens, with the objective of enhancing the immune response and boosting vaccine efficacy.